Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pozdeutinurad (Primary)
Indications Gout
Focus Registrational; Therapeutic Use
Acronyms REDUCE 2
Sponsors Arthrosi Therapeutics; Swedish Orphan Biovitrum

Most Recent Events

21 May 2026 According to Sobi media release , Detailed results are expected to be presented at a forthcoming scientific congress in Q4.
21 May 2026 Primary endpoint has been met. (Serum urate (uric acid) (sUA) level 6 mg/dL at month 6)
21 May 2026 Positive Topline Results presented at Sobi media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com